Management

Dr. Lui Franciosi, PhD

Dr. Lui Franciosi, PhD

Chief Executive Officer

Dr. Franciosi has more than 20 years of experience conducting pharmaceutical and medical device studies in academia and industry. Previously, he acted as the Chief Operating Officer at Verona Pharma PLC, London Stock Exchange (AIM: VRP). Prior to Verona Pharma, Dr. Franciosi completed his post-doctoral research in COPD progression modeling at the Clinical Pharmacology & Discovery Medicine Unit, GlaxoSmithKline, UK. He obtained his Doctorate & Masters degrees at The University of British Columbia (UBC), Canada – and pursued business studies at the University of Warwick, UK. He is currently an adjunct professor at UBC Faculty of Medicine, Department of Anesthesiology, Pharmacology & Therapeutics.

David Alexander, CPA /CA

David Alexander, CPA /CA

Chief Financial Officer

Mr. Alexander holds a Bachelor of Commerce in Finance from The University of British Columbia. His past achievements include; CFO of Arakis Energy Corporation, an international oil and gas development company, and managed the company’s growth from startup to over a billion dollars in assets, leading to a listing on the NASDAQ market. Arakis was subsequently sold to Talisman Energy. David was also CFO of Nortran Pharmaceuticals, Inc., a UBC based pharmaceutical company engaged in the development and commercialization of cardiovascular therapies. While at Nortran, David helped secure initial and ongoing research financing. Nortran ultimately became Cardiome Pharma, a successful Vancouver B.C. based pharmaceutical company (Nasdaq: CRME).

We have the skillset and the abilities to potentially substantiate claims surrounding marijuana for medicinal use. Not only from a scientific, but an intellectual property point of view, protecting our research and discovery in this exciting space.

Dr. Lui Franciosi

CEO

Dr. M. Scott Alexander, MBBS

Dr. M. Scott Alexander, MBBS

Medical Director

Dr. Alexander completed his medical degree at the University of Queensland in Brisbane, Australia. He earned his undergraduate and Masters degrees at Simon Fraser University in Burnaby, Canada. His Master’s thesis in neuroscience focused motor deficits in older adults with age-related macular degeneration. His research led to recommendations to civil engineers in designing enhanced environments for people with low-vision. Dr. Alexander’s undergraduate honour’s thesis was in behavioural neuroscience. He examined how perceptual shifts in visual input altered motor maps in the brain through the posterior parietal cortex, leading to long-term adaptations. This research has shown to help improve motor functions in individuals who have suffered debilitating strokes. During medical school, Dr. Alexander led two significant research projects. 1) A study in knowledge translation in the early detection and prevention of dementia. He coordinated Family Physician focus groups and extracted qualitative data from their conversations to drive practical research in dementia. 2) He validated a frailty assessment tool for rehabilitation inpatients, which monitored patient progress on a daily basis while in hospital.

Justin Kausel

Justin Kausel

Director of Business Development

Mr. Kausel is an energetic and driven business professional who for more than a decade has been developing startups with lasting success. With a background in business development, marketing and operations management, Justin has held positions as VP Marketing, Vice-President and Managing Director. Justin has seen success as a strategic consultant for three technology companies in the dental, healthcare and blockchain fields. He has extensive strategic & tactical experience from the startups in both Canadian and international markets. Justin has forged enduring relationships with C-suite teams at some of the world’s largest B2B and B2C companies and include Cadillac Fairview, Ivanhoe Cambridge, Oxford, Morguard, Audi, Bell, L’Oreal, Lexus, and Mercedes.

The Veritas Newsletter

Enter your email to receive news alerts and updates from Veritas Pharma.

You have Successfully Subscribed!